ARCHIVES

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Proposed Guidelines For Clinical Tests Of Oncologic Drugs

November 28, 1975

Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone

June 29, 2012

NCAB Approves CIS Recompetition, Restructuring

May 17, 1991

New Center Plan Discussed By NAB, Directors Committees

May 4, 1990

In Brief: Basic Research Chief At Frederick Will Be A Nominal Litton Employee To Avoid NCI Staff, Salary Ceilings

March 1, 1974

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014